8 recruiting, 1 not yet recruiting, 1 terminated, 1 unknown. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 8, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 2, Terminated 1, Unknown 1 |
Follow Advanced Prostate Cancer: new trials by email Literature Review of Advanced Prostate Cancer trials Research Report on Advanced Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer QLS2401 - Advanced Prostate Cancer | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 252 | 2026-11-06 | 2026-10-13 |
| DEC003M in Prostate Cancer DEC003M - Advanced Prostate Cancer | Phase 1 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2026-08-19 | 2026-10-14 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer GDC-1261 - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Genentech, Inc. | 260 | 2026-04-29 | 2026-10-06 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer HS-20093, HRS-5041 - Advanced Prostate Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 63 | 2025-08-19 | 2025-12-05 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib - Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 157 | 2025-05-07 | 2025-06-24 |
| Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT 18F-fluciclovine, PET/CT - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Recruiting | Brigham and Women's Hospital | 30 | 2024-02-01 | 2026-10-29 |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer HRS-4357 injection - Advanced Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 49 | 2023-09-30 | 2023-08-23 |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) HRS-5041, Docetaxel injection, Abiraterone acetate tablets - Advanced Prostate Cancer | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-08-03 | 2026-08-31 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer RO7656594 - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Recruiting | Genentech, Inc. | 210 | 2023-05-02 | 2026-11-03 |
| Study of HPN424 in Patients With Advanced Prostate Cancer HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target - Advanced Prostate Cancer | Phase 1 / Phase 2 | Terminated | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 104 | 2018-07-24 | 2024-02-14 |
Prostatic Neoplasms (5) · Breast Neoplasms (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1)
Genital Diseases (5) · Genital Diseases, Male (5) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Prostatic Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Adnexal Diseases (1) · Breast Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Abiraterone Acetate (2) · Docetaxel (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Irinotecan (1) · Platinum (1) · Positron Emission Tomography Computed Tomography (1) · Prednisone (1) · enzalutamide (1) · fluciclovine F-18 (1)
Genentech, Inc. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Brigham and Women's Hospital (1) · Hangzhou DAC Biotechnology Co., Ltd. (1) · Hansoh BioMedical R&D Company (1) · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Qilu Pharmaceutical Co., Ltd. (1) · Shanghai Qilu Pharmaceutical Research and Development Center LTD (1)
China (5) · United States (4) · United Kingdom (3) · Australia (2) · Canada (1) · France (1) · South Korea (1) · Spain (1)
2023 (1)